Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9%
Production / Operations

TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel

By The Northwire Desk — AI Analysis Feb 06, 2026 · 03:01 VIVI · 1.2 TempraMed Technologies Ltd.
VIVI · Price

Executive Summary

  • TempraMed Technologies announced the first commercial sales of its VIVI product line to pharmacies operated by Israel’s Maccabi Healthcare Services.
  • A nationwide in‑pharmacy marketing campaign has been launched across Maccabi’s network, making the products available at point‑of‑care for over 2.8 million insured members.
  • The rollout is presented as a key operational milestone that expands TempraMed’s institutional channel footprint and supports its broader growth strategy.

Key Details

  • Products Sold: VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med.
  • Customer/Partner: Maccabi Healthcare Services (Israel’s second‑largest HMO).
  • Coverage: Initial sales to Maccabi pharmacies; national marketing campaign to place products on shelves across the entire pharmacy network.
  • Target Population: Over 2.8 million insured members served by Maccabi.
  • Commercial Significance: First time TempraMed’s products will be sold directly to end‑customers in store and online within a large healthcare system, demonstrating ability to execute at scale.
  • Strategic Impact: Expected to drive recurring demand, strengthen brand presence in institutional channels, and serve as a platform for expansion into additional HMOs, payors, and institutional partners both in Israel and internationally.
  • CEO Quote (Ron Nagar): Highlights the milestone as proof of execution capability, growing demand for temperature‑protection solutions, and alignment with broader commercialization strategy.

Notable Quotes

“Shipping product and launching a nationwide campaign across the Maccabi brick‑and‑mortar pharmacy network demonstrates our ability to execute at scale within a large healthcare system.” – Ron Nagar, CEO, TempraMed Technologies Ltd.

Read the original news release →

More from TempraMed Technologies Ltd.

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 26, 2026 · 16:11

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 22, 2026 · 11:58

TempraMed Technologies Ltd.

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property